Free Trial
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel
NASDAQ:PEPG

PepGen Q3 2025 Earnings Results & Report

PepGen logo
$5.40 +0.79 (+17.22%)
As of 03:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

PepGen beat analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.52 versus the -$0.63 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

PepGen EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.63
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

PepGen Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

PepGen's Q3 2025 Earnings ReleaseEarnings Release
(8-K)
PepGen's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

PepGen Q3 2025 Earnings FAQ

PepGen (NASDAQ:PEPG) reported earnings of -$0.52 per share for Q3 2025, beating the consensus estimate of -$0.63. The report was announced on Wednesday, November 12, 2025.

PepGen Earnings Headlines

PepGen’s stock skyrockets on record-breaking DM1 trial data
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/pepgen-stock-skyrockets-record-breaking-181947497.html
PepGen Stock Soars 129% Despite Wider Q3 Loss
November 11 at 4:34 AM  |  rttnews.comhttps://www.rttnews.com/3712675/pepgen-stock-soars-129-despite-wider-q3-loss.aspx
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
November 11 at 1:00 AM  |  Profits Run (Ad)
PepGen stock soars over 100% on positive Phase 2 trial data for DM1 drug
November 11 at 4:34 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pepgen-stock-soars-over-100-140645055.html
Stock Traders Purchase Large Volume of Put Options on PepGen (NASDAQ:PEPG)
November 11 at 4:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31192545
PepGen reports phase 2 myotonic dystrophy trial results and $104.8 million cash position
November 10 at 11:34 PM  |  msn.comhttps://www.msn.com/en-us/money/other/pepgen-reports-phase-2-myotonic-dystrophy-trial-results-and-104-8-million-cash-position/ar-AA2h9Jak
See More PepGen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PepGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PepGen and other key companies, straight to your email.

About PepGen

PepGen (NASDAQ:PEPG) Inc. is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing.

PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue. The company’s research and development efforts have focused primarily on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

Its lead programs include PGN-EDO51, an exon-skipping therapy being developed for a subset of patients with DMD who may benefit from exon 51 skipping, and PGN-EDODM1, an investigational treatment designed to address the underlying RNA-processing defects associated with DM1. PepGen is based in the United States and is advancing these programs through clinical development. James McNally serves as the company’s president and chief executive officer.

View PepGen Profile
Earnings Tools